Ämnen: Haelso-sjukvaard
-
Sanofi får europeiskt godkännande för ZALTRAP (aflibercept) för behandling av metastaserad kolorektal cancer
-
Lyxumia® (lixisenatid) får europeiskt godkännande för behandling av typ 2-diabetes
-
Sanofi President, Global Operations, to retire
-
Sanofi Ranks Third on the Access to Medicine Foundation’s 2012 ATM Index
-
Att leva med förmaksflimmer
-
Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet
-
New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population
-
Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint
-
FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis
-
Anna-Kaija Grönblad ny vd för Sanofi Sverige
-
Genzyme Provides Update on U.S. LEMTRADA™(*) Filing
-
För dig som älskar uteliv: Nya gratisappen Parkguiden visar vägen till parken
-
Allegra lindrar säsongsbundna pollenallergier
- Licens:
- Creative Commons erkännande
- Filformat:
- .jpg
- Storlek:
- 1595 x 1063, 656 KB
-
Europeiska läkemedelsmyndigheten (EMA) bekräftar positiv bedömning av nytto-riskbalansen för MULTAQ®
-
Sanofi Announces New Long Term Objectives
-
Sanofi Establishes a Global Agreement with Medco and UBC to Improve Quality of Patient Care through Real-World Evidence
-
Sanofi GetGoal Program on Lyxumia®, as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results
-
Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement to Generate New Drugs for Neglected Tropical Diseases
-
Data at ASCO Showcase Sanofi’s Commitment to Research and Identify Treatments for Cancer Patients
Visa mer
Loading...